Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Slides:



Advertisements
Similar presentations
Triple-Negative and BRCA-Mutated Metastatic Breast Cancer
Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
The Nurse View: Management of Pancreatic Cancer
State of the Art in BRCA-Mutated Ovarian Cancer
The Nurse View.
The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer
Perspectives on Triple-Negative Breast Cancer
Advanced NSCLC Without Actionable Mutations
BRCA, HRR Deficiency, and PARP Inhibitors
New Patient Journeys in Non-small cell lung cancer
The Nurse View.
Metastatic Renal Cell Carcinoma
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
PARP Inhibitors and Cancer: What Do You Need to Know?
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Counseling Patients About Germline BRCA Mutations
Optimizing Management of Advanced Bladder Cancer
Managing gBRCA-Positive Metastatic Breast Cancer
Individualizing Care in Ovarian Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
More Than Meets the Eye.
Advancing Care in Genitourinary Cancer: Perspectives From Chicago
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Advancing Care Across the Spectrum of Pancreatic Cancer
PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
Maintenance Therapy in Advanced Ovarian Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
Molecular Testing in Ovarian Cancer: Is the Time Now?
Non-Chemotherapy Combinations in CLL
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Changing Field of Melanoma: Ipilimumab.
New Paradigms in HR-Positive Advanced Breast Cancer
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Practical Guidance on the Management of Pan-Negative NSCLC
(A) Safety profile overview.
Preparing for Checkpoint Inhibitors in Breast Cancer
Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Checkpoint Inhibitors in First-Line Advanced NSCLC
Optimizing Outcomes in Patients With NSCLC and Liver Metastases
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
Moving Care Forward in Advanced Gastric Cancer
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Clinical Focus.
Identifying TRK Fusions in Head and Neck Cancer
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.
Understanding the Expanding Armamentarium for GIST
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Uncovering the Right Sequence
Presentation transcript:

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer

Overview of Metastatic TNBC

Case 1: Introduction

OlympiAD: Olaparib in Patients With mBC and Germline BRCA Mutations

EMBRACA: Talazoparib in Patients With mBC and Germline BRCA Mutations

Using PARP Inhibitors in BRCA-Mutated MBC

Case 2: Introduction

First-Line Treatment of mTNBC IMpassion130: Nab-Paclitaxel + Atezolizumab

Testing for PD-L1 in Patients With TNBC

Considerations With Checkpoint Inhibitors

Treatment of PD-L1-Negative, Germline BRCA-WT mTNBC

What About Chemotherapy Doublets? Expert Perspectives

What If Patients Are PD-L1-Positive and Germline BRCA Mutation-Positive?

Second- and Third-Line Treatment of mTNBC

Making Treatment Decisions in mTNBC

Considering Clinical Trials in mTNBC

Future Directions in mTNBC: Antibody-Drug Conjugates

Future Directions in mTNBC: Other Approaches

Shared Decision-Making Principles

Direct Patients to Reputable Resources

Key Takeaways

Abbreviations

Abbreviations (cont)